Keyword Analysis & Research: trefoil therapeutics


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
trefoil therapeutics0.330.989672920
trefoil1.681275147
therapeutics1.830.798152112

Keyword Research: People who searched trefoil therapeutics also searched

Keyword CPC PCC Volume Score
trefoil therapeutics0.350.4908875

Search Results related to trefoil therapeutics on Search Engine

  • Trefoil therapeutics

    trefoiltherapeutics.com

    https://trefoiltherapeutics.com/

    Oops! Something went wrong, please try again later.Add hours

    DA: 71 PA: 90 MOZ Rank: 55

  • Trefoil therapeutics

    trefoiltherapeutics.com

    https://trefoiltherapeutics.com/

    WEBMay 10, 2023 · We are dedicated to restoring sight to the millions of people with corneal diseases through the advancement of therapies based on the inherent regenerative …

    DA: 1 PA: 64 MOZ Rank: 95

  • Trefoil Therapeutics Announces Third Tranche of $28 Million Series …

    trefoiltherapeutics.com

    https://trefoiltherapeutics.com/trefoil-therapeutics-announces-third-tranche-of-28-million-series-a-financing-based-on-achievement-of-clinical-trial-objectives/

    WEBSan Diego, CA, December 1, 2021 – Trefoil Therapeutics today announced that after review of the interim clinical data from the INTREPID and STORM studies, the Series A investors …

    DA: 76 PA: 80 MOZ Rank: 63

  • Trefoil Therapeutics Announces Positive TTHX1114 Phase 2 Study …

    businesswire.com

    https://www.businesswire.com/news/home/20220929005034/en/Trefoil-Therapeutics-Announces-Positive-TTHX1114-Phase-2-Study-Data-Showing-Corneal-Regeneration-and-Vision-Recovery-Following-Descemet-Stripping-Only-DSO-Surgery

    WEBSep 29, 2022 · San Diego-based Trefoil Therapeutics is a clinical-stage biotechnology company focused on leveraging its engineered FGF1 protein technology platform to …

    DA: 65 PA: 46 MOZ Rank: 49

  • Restoring vision loss with a regenerative therapy - Nature

    nature.com

    https://www.nature.com/articles/d43747-021-00060-8

    WEBTrefoil Therapeutics has responded by developing TTHX1114, a novel, regenerative product, now in proof-of-concept clinical trials. A major therapeutic and commercial opportunity …

    DA: 95 PA: 6 MOZ Rank: 37

  • Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial …

    trefoiltherapeutics.com

    https://trefoiltherapeutics.com/trefoil-therapeutics-begins-second-phase-2-storm-clinical-trial-with-regenerative-treatment-for-fuchs-endothelial-corneal-dystrophy/

    WEBSan Diego, CA – February 9, 2021 – Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its …

    DA: 95 PA: 44 MOZ Rank: 77

  • Trefoil Therapeutics Begins Second Phase 2 “STORM” Clinical Trial …

    businesswire.com

    https://www.businesswire.com/news/home/20210209005323/en/Trefoil-Therapeutics-Begins-Second-Phase-2-%E2%80%9CSTORM%E2%80%9D-Clinical-Trial-with-Regenerative-Treatment-for-Fuchs-Endothelial-Corneal-Dystrophy

    WEBFeb 9, 2021 · Trefoil Therapeutics is a private biotechnology company focused on leveraging its engineered FGF-1 protein technology platform to develop first-in-class pharmacologic …

    DA: 28 PA: 69 MOZ Rank: 17